Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis Announces U.S. Patent Issuance Strengthening Intellectual Property Position of PI3K-HDAC Inhibitor CUDC-907

Globe Newswire June 20, 2013

Curis to Present at the 2013 Wells Fargo Securities Healthcare Conference

Globe Newswire June 11, 2013

Curis Announces CUDC-427 (GDC-0917) Phase I Clinical Data Presented at ASCO 2013 Annual Meeting

Globe Newswire June 3, 2013

Curis Announces Appointment of Mani Mohindru, Ph.D., as Vice President of Corporate Strategy and Investor Relations

Globe Newswire May 31, 2013

Curis to Present at the Jefferies 2013 Global Healthcare Conference

Globe Newswire May 30, 2013

Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference

Globe Newswire May 22, 2013

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

Globe Newswire May 16, 2013

Curis Announces Approval of Erivedge(R) in Australia

Globe Newswire May 10, 2013

Curis Reports First Quarter 2013 Financial Results

Globe Newswire April 30, 2013

Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union

Globe Newswire April 26, 2013

Curis to Present at the Needham 12th Annual Healthcare Conference

Globe Newswire April 24, 2013

Curis to Release First Quarter 2013 Financial Results and Hold Conference Call on April 30, 2013

Globe Newswire April 23, 2013

Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

Globe Newswire March 29, 2013

Curis Announces Appointment of Kenneth Pienta, M.D. to Board of Directors

Troy Schwensen March 11, 2013

Curis to Present at the Roth Capital Partners 25th Annual Growth Stock Conference

Troy Schwensen March 11, 2013

Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success in 2012

Marketwired March 4, 2013

Curis to Present at the Cowen and Company 33rd Annual Health Care Conference

Troy Schwensen February 25, 2013

Curis Appoints Ali Fattaey, Ph.D. as President and Chief Operating Officer

Troy Schwensen February 19, 2013

Curis to Present at Upcoming Investor Conferences

Troy Schwensen February 15, 2013

Curis to Release Fourth Quarter and Year End 2012 Financial Results and Hold Conference Call on February 20, 2013

Troy Schwensen February 13, 2013